- Home
- IGC vs PMN Comparison
IGC vs PMN Comparison
Compare IGC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IGC | PMN |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 23.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IGC | PMN |
|---|---|---|
| Price | $0.29 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.13 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 634.9K | 15.6K |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,106,000.00 | N/A |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $15.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $6.27 |
| 52 Week High | $0.50 | $39.75 |
Technical Indicators
Market Signals| Indicator | IGC | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 64.61 |
| Support Level | $0.29 | $8.08 |
| Resistance Level | $0.30 | $8.51 |
| Average True Range (ATR) | 0.01 | 0.43 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 20.75 | 84.06 |
Price Performance
Historical ComparisonAbout IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.